RU2016130327A - BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION - Google Patents

BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION Download PDF

Info

Publication number
RU2016130327A
RU2016130327A RU2016130327A RU2016130327A RU2016130327A RU 2016130327 A RU2016130327 A RU 2016130327A RU 2016130327 A RU2016130327 A RU 2016130327A RU 2016130327 A RU2016130327 A RU 2016130327A RU 2016130327 A RU2016130327 A RU 2016130327A
Authority
RU
Russia
Prior art keywords
blood substitute
pharmaceutical composition
substitute according
blood
oxygen transfer
Prior art date
Application number
RU2016130327A
Other languages
Russian (ru)
Inventor
Анна Яковлевна Гончарова
Рахимджан Ахметджанович Розиев
Виктор Владимирович Хомиченок
Руслан Александрович Земляной
Original Assignee
Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" filed Critical Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм"
Priority to RU2016130327A priority Critical patent/RU2016130327A/en
Publication of RU2016130327A publication Critical patent/RU2016130327A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (9)

1.     Кровезаменитель с функцией переноса кислорода в виде сухой субстанции, содержащий не менее 90% полимеризованного гемоглобина крови животных, с молекулярной массой в диапазоне 192000-320000 Да и с содержанием метгемоглобина в кровезаменителе не более 5%, глицин или глюкозу, отличающийся соотношением компонентов: 1. Blood substitute with the function of oxygen transfer in the form of a dry substance, containing not less than 90% polymerized hemoglobin of animal blood, with a molecular weight in the range of 192000-320000 Yes and methemoglobin in the blood substitute not more than 5%, glycine or glucose, characterized by a ratio of components: - полимеризованный гемоглобин от 30 до 80%- polymerized hemoglobin from 30 to 80% - глицин или глюкоза от 20 до 50%.- glycine or glucose from 20 to 50%. 2.     Кровезаменитель по п.1, отличающийся тем, что он дополнительно содержит натрия хлорид от 5 до 10%.2. The blood substitute according to claim 1, characterized in that it additionally contains sodium chloride from 5 to 10%. 3.   Кровезаменитель по п.1, отличающийся тем, что он дополнительно содержит аскорбиновую кислоту от 0.5 до 2%. 3. The blood substitute according to claim 1, characterized in that it further comprises ascorbic acid from 0.5 to 2%. 4.  Кровезаменитель по п.4, отличающийся тем, что представляет собой порошок с влажностью не более 7%.4. The blood substitute according to claim 4, characterized in that it is a powder with a moisture content of not more than 7%. 5.     Кровезаменитель по п.4, отличающийся тем, что представляет собой гранулы с влажностью не более 7%.5. Blood substitute according to claim 4, characterized in that it represents granules with a moisture content of not more than 7%. 6.     Фармацевтическая композиция, содержащая кровезаменитель по п.1 и полиоксидин, содержащий 1,5%-ный раствор полиэтиленгликоля с молекулярной массой 20 кДа в 0,9% раствора хлорида натрия с добавлением йодида калия.6. The pharmaceutical composition containing the blood substitute according to claim 1 and polyoxidine containing a 1.5% solution of polyethylene glycol with a molecular weight of 20 kDa in a 0.9% solution of sodium chloride with the addition of potassium iodide. 7. Фармацевтическая композиция, содержащая кровезаменитель по п.1 и 6%-ный раствор поливинилпирролидона с молекулярной массой 12,6 кДа с добавлением сбалансированных по ионному составу солей. 7. The pharmaceutical composition containing the blood substitute according to claim 1 and a 6% solution of polyvinylpyrrolidone with a molecular weight of 12.6 kDa with the addition of salts balanced in ionic composition.
RU2016130327A 2016-07-25 2016-07-25 BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION RU2016130327A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2016130327A RU2016130327A (en) 2016-07-25 2016-07-25 BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016130327A RU2016130327A (en) 2016-07-25 2016-07-25 BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016106011A Division RU2016106011A (en) 2016-02-21 2016-02-21 BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION (OPTIONS)

Publications (1)

Publication Number Publication Date
RU2016130327A true RU2016130327A (en) 2018-01-30

Family

ID=61173962

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016130327A RU2016130327A (en) 2016-07-25 2016-07-25 BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION

Country Status (1)

Country Link
RU (1) RU2016130327A (en)

Similar Documents

Publication Publication Date Title
JP2019069238A5 (en)
ES2677603T3 (en) Precursor Dialysis Composition
RU2012125877A (en) NUTRITIONAL EMULSIONS CONTAINING BETA-HYDROXY-BETA-METALBUTYRATE CALCIUM (GMB CALCIUM) AND SOLUBLE PROTEIN
JP2010280671A5 (en)
RU2016132386A (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITHOUT GLYCERIN BASED ON INSULIN ANALOGUES AND / OR INSULIN DERIVATIVES
US3560380A (en) Dry concentrates for preparing hemodialysis solutions
EA200701660A1 (en) COMPOSITIONS AND METHODS INTENDED FOR THE RETAILED STORAGE OF ERYTHROCYTES
Kampmeier et al. Evolution of fluid therapy
MY178888A (en) Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same
RU2016147362A (en) DRUGS OF LIQUID CONCENTRATE OF CYCLOPHOSPHAMIDE
ES2587862T3 (en) Precursor Dialysis Composition
MY176214A (en) Three-pack type dialysis agent containing acetic acid and acetic acid salt
ZA201504284B (en) Solution for preserving vascular conduits
EA201390090A1 (en) DISINFECTANT AND ANTI-SECONDARY DRUG WITH A REDUCED CONTENT OF IODINE
EA201001469A1 (en) STABILIZER WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION (OPTIONS)
Jensen et al. Nitric oxide metabolites during anoxia and reoxygenation in the anoxia-tolerant vertebrate Trachemys scripta
IL310557A (en) Stable protein compositions
EA201190285A1 (en) IMMUNOGENOUS COMPOSITIONS WITH LOW CONCENTRATION OF SODIUM CHLORIDE
JP2015522632A5 (en)
RU2016130327A (en) BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION
DK2068842T3 (en) Active substance and trimagnesium dicrate as stabilized solid pharmaceuticals containing desiccant and process for their preparation
RU2016106011A (en) BLOOD SUBSTITUTE WITH OXYGEN TRANSFER FUNCTION, PHARMACEUTICAL COMPOSITION (OPTIONS)
MX2022010192A (en) Transdermal absorption preparation.
RU2010145064A (en) DRY TRANSGLUTAMINASE COMPOSITION
RU2020128269A (en) HIGHLY STABLE THYROID HORMONE DOSAGE FORMS IN SOFT CAPSULES

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20190726